Microcirculatory disorders in sepsis and transplantation: Therapy with natural coagulatory inhibitors antithrombin and activated protein C

Current Opinion in Critical Care

Volumn 12, Issue 5, 2006, Pages 426-430

  Hoffmann, Johannes N ^a,b   Fertmann, Jan M ^a   Jauch, K W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Activated protein C; Antithrombin; Coagulatory inhibition; Ischemia reperfusion; Microvascular dysfunction; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING INHIBITOR; DANAPAROID; HEPARIN;

CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; ENDOTOXEMIA; HUMAN; KIDNEY PERFUSION; KIDNEY TRANSPLANTATION; MICROANGIOPATHY; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PANCREATITIS; REPERFUSION INJURY; REVIEW; SEPSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; HUMANS; MICROCIRCULATION; MODELS, ANIMAL; ORGAN TRANSPLANTATION; PROTEIN C; RATS; REPERFUSION INJURY; SEPSIS;

EID: 33748428053     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000244121.54495.f7     Document Type: Review

References (43)

1. Ince C. The microcirculation is the motor of sepsis. Crit Care 2005; 9:S13-S19. Clear and excellent overview about the pathogenesis and the role of microcirculatory disorders in sepsis.
2. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420:885-891.
3. De Backer D, Creteur J, Pricer JC, et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166:98-104.
4. Hoffmann JN, Vollmar B, Inthorn D, et al. A chronic model for intravital microscopic study of microcirculatory disorders and leukocyte/endothelial cell interaction during normotensive endotoxinemia. Shock 1999; 12:355-364.
5. Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89:4268-4274.
6. Hoffmann JN, Faist E. Coagulation inhibitor replacement during sepsis: Useless? Crit Care Med 2000; 28:S74-S76.
7. Tanaka T, Tsujinaka T, Kambayashi J, et al. Sepsis model with reproducible manifestations of multiple organ failure (MOF) and disseminated intravascular coagulation (DIC). Thromb Res 1989; 54:53-61.
8. Johnson K, Aarden L, Choi Y, et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87:5051-5060.
9. Levi M, de Jonge E, van der Poll T, ten Cate H. Novel approaches to the management of disseminated intravascular coagulation. Crit Care Med 2000; 28:S20-S24.
10. Iba T, Kidokoro A, Fukunaga M, et al. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005; 23:25-29. This paper clearly shows the association between inflammation, hemostasis and endothelial injury in human sepsis.
11. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrin 2002; 13:657-670.
12. Hoffmann JN, Vollmar B, Laschke MW, et al. Microcirculatory alterations in ischemia reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition. Crit Care 2005; 9:S33-S37. This paper gives an overview about the effects of thrombin inhibition, and coagulatory inhibitor application in ischemia reperfusion and sepsis with a focus on activated protein C.
13. Harada N, Okajima K, Kushimoto S, et al. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93:157-164.
14. Maria Riva C, Morganroth ML, Ljungman AG, et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol 1990; 3:301-309.
15. Özden A, Tetik C, Bilgihan A, et al. Antithrombin III prevents 60 min warm intestinal ischemia reperfusion injury in rats. Res Exp Med 1999; 198:237-246.
16. Duru S, Koca U, Öztekin S, et al. Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study. Acta Anaesthesiol Scand 2005; 49:1142-1148. This experimental paper for the first time analyzes the reduction of pulmonary damage after limb ischemia via antithrombin application.
17. Aytekin FO, Tekin K, Kabay B, et al. Antithrombin attenuates pulmonary tissue injury caused by mesenteric ischemia reperfusion. Am J Surg 2005; 189:161-166. This paper shows that mesenteric ischemia reperfusion related pulmonary injury can be prevented by high-dosed antithrombin application.
18. Ostrovsky L, Woodman R, Payne D, et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997; 96:2302-2310.
19. Schoots IG, Levi M, van Vliet AK, et al. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004; 32:1375-1383.
20. Takeshita K, Arakawa K, Okamoto M. The anticoagulant effect of antithrombin III on hyperacute xenograft rejection. Transplant Proc 1996; 28:631-632.
21. Arakami O, Takayama T, Yokoyama T, et al. High dose of AT induces indefinite survival of fully allogenic cardiac grafts and generates regulatory cells. Transplantation 2003; 75:217-220.
22. Hoffmann JN, Arbogast HP, Fertmann J, et al. High dose antithrombin therapy reduces ischemia/reperfusion injury during human allogenic kidney transplantation: first results of a randomized controlled clinical trial. Transplantation 2002; 74:394-395.
23. Fertmann JM, Wimmer CD, Arbogast HP, et al. Single-shot antithrombin in human pancreas-kidney transplantation: reduction of reperfusion pancreatitis and prevention of graft thrombosis. Transpl Int 2006; 19:458-465. This recent paper gives evidence from a clinical trial using high-dosed single shot antithrombin application to reduce venous graft thrombosis and to improve graft reperfusion and function in patients with pancreas-kidney transplantation.
24. Hoffmann JN, Vollmar B, Inthorn D, et al. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol 2000; 279:C98-C107.
25. Hoffmann JN, Vollmar B, Roemisch J, et al. Antithrombin effects on endotoxin-induced microcirculatory disorders are mainly mediated by its interaction with microvascular endothelium. Crit Care Med 2002; 30:218-225.
26. Hoffmann JN, Vollmar B, Inthorn D, et al. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/endothelial cell interaction and microvascular perfusion failure. Shock 2000; 14:528-534.
27. Neviere R, Tournoys A, Mordon S, et al. Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 2001; 15:220-225.
28. Yamashiro K, Kiryu J, Tsujikawa A, et al. Inhibitory effects of antithrombin III against leukocyte rolling and infiltration during endotoxin-induced uveitis in rats. Invest Ophtalmol Vis Sci 2001; 42:1553-1560.
29. Iba T, Kidokoro A, Fukunaga M, et al. Antithrombin modulates the leukocyte endothelial cell interaction in the staphylococcal enterotoxin B-challenged mouse. J Trauma 2003; 55:546-550.
30. Maksan SM, Gebhard MM, Schmidt J. Impact of antithrombin on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: an in vivo analysis. World J Gastroenterol 2005; 11:4997-5001. This paper represents an elegant intravital microscopic analysis of antithrombin effects in nonseptic bowel inflammation and liver cirrhosis.
31. Hoffmann JN, Vollmar B, Laschke M, et al. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002; 88:242-252.
32. Iba T, Kidokoro A, Fukunaga M, et al. Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin. Intensive Care Med 2005; 31:1101-1108. This recent paper shows that the heparin-antithrombin antagonism may be not relevant when using a more specific Xa inhibitor (danaparoid sodium).
33. Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985; 39:81-89.
34. Hoffmann JN, Wiedermann CJ, Juers M, et al. KyberSept investigators. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006; 95:850-856. The analysis of the subgroups of patients in the KyberSept trial with and without concomitant heparin gives clear evidence for the avoidance of heparin when using AT effects in sepsis.
35. Kienast J, Juers M, Wiedermann CJ, et al. KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006; 4:90-97. New analysis of patients with DIC according to ISTH criteria in the KyberSept trial showing that AT is more effective in patients with DIC.
36. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95:3781-3787.
37. Yamaguchi Y, Hisama N, Okajima K, et al. Pretreatment with activated protein C or active human urinary thrombomodulin attenuates the production of cytokine-induced neutrophil chemoattractant following ischemia reperfusion. Hepatology 1997; 25:1136-1140.
38. Roback MG, Stack AM, Thompson C, et al. Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock 1998; 9:138-142.
39. Murakami K, Okajima K, Uchiba M. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87:642-647.
40. Grinnell BW, Herman RB, Yan SB. Human protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide. Glycobiology 1994; 4:221-224.
41. Iba T, Kidokoro A, Fukunaga M, et al. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33:368-372. Very elegant analysis of the visceral microcirculation in endotoxemia when giving prophylactic antithrombin.
42. De Backer D, Verdant C, Chierego M, et al. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 2006; 34:1918-1924. First proof that APC is also influencing microcirculation in humans and simultaneously improving organ dysfunction scores.
43. Boerma EC, Mathura KR, van der Voort PHJ, et al. Quantifying bedside-derived imaging of microcirculatory abnormalities in septic patients: a prospective validation study. Critical Care 2005; 9:R601-R606. Comprehensive review on techniques for the measurement of microvascular perfusion in humans.